114 related articles for article (PubMed ID: 18379032)
21. Comparison of phenotype of gammadelta T cells generated using various cultivation methods.
Mehrle S; Watzl C; von Lilienfeld-Toal M; Amoroso A; Schmidt J; Märten A
Immunol Lett; 2009 Jun; 125(1):53-8. PubMed ID: 19505505
[TBL] [Abstract][Full Text] [Related]
22. In vivo application of mAb directed against the gammadelta TCR does not deplete but generates "invisible" gammadelta T cells.
Koenecke C; Chennupati V; Schmitz S; Malissen B; Förster R; Prinz I
Eur J Immunol; 2009 Feb; 39(2):372-9. PubMed ID: 19130484
[TBL] [Abstract][Full Text] [Related]
23. The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity.
Chitadze G; Oberg HH; Wesch D; Kabelitz D
Trends Immunol; 2017 Sep; 38(9):668-678. PubMed ID: 28709825
[TBL] [Abstract][Full Text] [Related]
24. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
25. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
[TBL] [Abstract][Full Text] [Related]
26. Activation of γδ T cells by bisphosphonates.
Thompson K; Roelofs AJ; Jauhiainen M; Mönkkönen H; Mönkkönen J; Rogers MJ
Adv Exp Med Biol; 2010; 658():11-20. PubMed ID: 19950011
[TBL] [Abstract][Full Text] [Related]
27. Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more.
Dieli F; Caccamo N; Meraviglia S
Curr Opin Investig Drugs; 2008 Oct; 9(10):1089-94. PubMed ID: 18821471
[TBL] [Abstract][Full Text] [Related]
28. Imaging the immune response to monitor tumor immunotherapy.
Wang Q; Ornstein M; Kaufman HL
Expert Rev Vaccines; 2009 Oct; 8(10):1427-37. PubMed ID: 19803763
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell-based cancer immunotherapies.
Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
[TBL] [Abstract][Full Text] [Related]
30. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effects of bisphosphonates: promising preclinical evidence.
Guise TA
Cancer Treat Rev; 2008; 34 Suppl 1():S19-24. PubMed ID: 18486348
[TBL] [Abstract][Full Text] [Related]
32. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
33. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
Chen Z; Freedman MS
Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
[TBL] [Abstract][Full Text] [Related]
34. Human gamma delta T cells and tumor immunotherapy.
Tanaka Y
J Clin Exp Hematop; 2006 Mar; 46(1):11-23. PubMed ID: 17058804
[TBL] [Abstract][Full Text] [Related]
35. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells.
Martinet L; Fleury-Cappellesso S; Gadelorge M; Dietrich G; Bourin P; Fournié JJ; Poupot R
Eur J Immunol; 2009 Mar; 39(3):752-62. PubMed ID: 19197941
[TBL] [Abstract][Full Text] [Related]
36. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
[TBL] [Abstract][Full Text] [Related]
37. Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more.
Caccamo N; Meraviglia S; Scarpa F; La Mendola C; Santini D; Bonanno CT; Misiano G; Dieli F; Salerno A
Expert Opin Biol Ther; 2008 Jul; 8(7):875-83. PubMed ID: 18549319
[TBL] [Abstract][Full Text] [Related]
38. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
[TBL] [Abstract][Full Text] [Related]
39. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
Jorritsma A; Bins AD; Schumacher TN; Haanen JB
Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
[TBL] [Abstract][Full Text] [Related]
40. What lessons can be learned from γδ T cell-based cancer immunotherapy trials?
Fournié JJ; Sicard H; Poupot M; Bezombes C; Blanc A; Romagné F; Ysebaert L; Laurent G
Cell Mol Immunol; 2013 Jan; 10(1):35-41. PubMed ID: 23241899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
